Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trialBARRETT, S. V; PAUL, J; HAY, A et al.Annals of oncology. 2008, Vol 19, Num 5, pp 898-902, issn 0923-7534, 5 p.Article

SCOTROC 2B : feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancerCLAMP, A. R; MÄENPÄÄ, J; JAYSON, G. C et al.British journal of cancer. 2006, Vol 94, Num 1, pp 55-61, issn 0007-0920, 7 p.Article

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line Chemotherapy for ovarian carcinomaVASEY, Paul A; JAYSON, Gordon C; GORDON, Alan et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 22, pp 1682-1691, issn 0027-8874, 10 p.Article

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancersVASEY, P. A; GORE, M; WILSON, R et al.British journal of cancer. 2008, Vol 98, Num 11, pp 1774-1780, issn 0007-0920, 7 p.Article

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancerVASEY, P. A; PAUL, J; THOMAS, H et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2069-2080, issn 0732-183XArticle